NLS Intellectual Property

Orexo has recently entered a settlement agreement with Sun Pharmaceuticals Industries to resolve a patent litigation regarding the company's Zubsolv sublingual tablet for the treatment of opioid use disorder in the US. NLS asked Nikolaj Sørensen, CEO of Orexo, about the impact of this settlement and his thoughts on the patent litigation process and generic challenges.

Orexo has entered into a settlement agreement with Sun Pharmaceuticals Industries to resolve the patent litigation regarding Zubsolv (buprenorphine and naloxone) sublingual tablet (CIII), for the treatment of opioid use disorder in the US.

The company has been granted a US patent for its SiPore platform technology.

Abera Bioscience has received the final decision to approve its patent application “Display of heterologous molecules on bacterial cells and membrane vesicles” from the European Patent Office (EPO).

Mucocort has been granted a patent in China for its product/technology, which has previously been approved under the European Patent System (EPC).

IRLAB Therapeutics has announced that the company has been granted a new patent in Europe, which includes a new salt of mesdopetam used throughout the clinical development process and the process of its preparation. The patent that has now been granted extends the already strong patent protection for mesdopetam, the company’s most advanced project. “The […]